These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 17038512)

  • 1. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
    Marquis KL; Sabb AL; Logue SF; Brennan JA; Piesla MJ; Comery TA; Grauer SM; Ashby CR; Nguyen HQ; Dawson LA; Barrett JE; Stack G; Meltzer HY; Harrison BL; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 2007 Jan; 320(1):486-96. PubMed ID: 17038512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity.
    Dunlop J; Sabb AL; Mazandarani H; Zhang J; Kalgaonker S; Shukhina E; Sukoff S; Vogel RL; Stack G; Schechter L; Harrison BL; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 2005 May; 313(2):862-9. PubMed ID: 15705738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study.
    Di Giovanni G; Di Matteo V; Di Mascio M; Esposito E
    Synapse; 2000 Jan; 35(1):53-61. PubMed ID: 10579808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD; Harting J; Minck KO
    J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
    J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics.
    Grauer SM; Graf R; Navarra R; Sung A; Logue SF; Stack G; Huselton C; Liu Z; Comery TA; Marquis KL; Rosenzweig-Lipson S
    Psychopharmacology (Berl); 2009 May; 204(1):37-48. PubMed ID: 19107466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of escitalopram and a 5-HT(₁A) receptor antagonist selectively decreases the extracellular levels of dopamine in the nucleus accumbens relative to striatum through 5-HT(₂C) receptor stimulation; suggestive of antipsychotic potential.
    Hovelsø N; Sager TN; Mørk A
    Pharmacol Biochem Behav; 2011 Jan; 97(3):479-85. PubMed ID: 20937301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of dopamine release by striatal 5-HT2C receptors.
    Alex KD; Yavanian GJ; McFarlane HG; Pluto CP; Pehek EA
    Synapse; 2005 Mar; 55(4):242-51. PubMed ID: 15668911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The acute and chronic administration of the 5-HT(2B/2C) receptor antagonist SB-200646A significantly alters the activity of spontaneously active midbrain dopamine neurons in the rat: An in vivo extracellular single cell study.
    Blackburn TP; Suzuki K; Ashby CR
    Synapse; 2006 Jun; 59(8):502-12. PubMed ID: 16565966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal.
    Broderick PA; Hope O; Okonji C; Rahni DN; Zhou Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):157-71. PubMed ID: 14687870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration.
    Di Matteo V; Pierucci M; Esposito E
    J Neurochem; 2004 Apr; 89(2):418-29. PubMed ID: 15056285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SR146131, a cholecystokinin-A receptor agonist, antagonizes prepulse inhibition deficits produced by dizocilpine and DOI.
    Shilling PD; Feifel D
    Psychopharmacology (Berl); 2002 Nov; 164(3):285-93. PubMed ID: 12424552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of serotonin2C receptors blocks the hyperactivation of midbrain dopamine neurons induced by nicotine administration.
    Pierucci M; Di Matteo V; Esposito E
    J Pharmacol Exp Ther; 2004 Apr; 309(1):109-18. PubMed ID: 14722316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Region-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin2C receptors.
    Navailles S; Moison D; Ryczko D; Spampinato U
    J Neurochem; 2006 Nov; 99(4):1311-9. PubMed ID: 17018023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats.
    Zaniewska M; McCreary AC; Przegaliński E; Filip M
    Eur J Pharmacol; 2007 Oct; 571(2-3):156-65. PubMed ID: 17617403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.